10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Items 601–700 of 1,169
Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · Diabetes Care · doi:10.2337/dc11-s221 · Cited by 147
“Results from the Diabetes Control and Complications Trial (3) (8a), UK Prospective Diabetes Study (4,5), and other trials (9a) have established hyperglycemia as the major risk factor for microvascular and, to a lesser extent, macrovascular (6) (10a,11a) complications.”
BackgroundGlycaemic management in diabetes: old and new approaches
Ceriello, A., Prattichizzo, F., Phillip, M., Hirsch, I. B., Mathieu, C., & Battelino, T. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00245-x · Cited by 139
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Ahren, B. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33934 · Cited by 148
“Hypoglycemia as a factor behind clinical inertia Intensive glucose control is an important glucose-lowering strategy in the treatment of type 2 diabetes to reduce the risk for diabetic complications.(1) Intense glucose lowering is achieved in many patients by a combination of medications, including sulfonylureas and i…”
Strambini, L. M., Longo, A., Scarano, S., Prescimone, T., Palchetti, I., Minunni, M., Giannessi, D., & Barillaro, G. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.11.010 · Cited by 154
“…of serious complications (American Diabetes Association, 2010) in diabetic patients (DPs) and, in turn, deaths (UK Prospective Diabetes Study (UKPDS) Group, 1998; Holman et al., 2008; The Diabetes Control and Complications Trial Research Group, 1993; Nathan et al., 2005; Kitzmiller et al., 2008).”
BackgroundEffects of Intensive Glucose Lowering in Type 2 Diabetes
Schinner, S. (2009) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(09)79280-7 · Cited by 148
Natural Nrf2 activators in diabetes
Jiménez‐Osorio, A. S., González-Reyes, S., & Pedraza‐Chaverrí, J. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.07.009 · Cited by 161
Intensified glucose lowering in type 2 diabetes: time for a reappraisal
Yudkin, J. S., Richter, B., & Gale, E. A. M. (2010) · Diabetologia · doi:10.1007/s00125-010-1864-z · Cited by 156
Know the signs and symptoms of diabetes.
Ramachandran, A. (2014) · PubMed Central · Cited by 275
Metformin: A Novel Weapon Against Inflammation
Bai, B., & Chen, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.622262 · Cited by 161
Zelmanovitz, T., Gerchman, F., Balthazar, A. P., Thomazelli, F. C. S., de Matos, J. D., & Canani, L. H. S. (2009) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-1-10 · Cited by 184
“In type 1 and type 2 subjects the effect of intensive therapy could be seen many years later [108,111].”
BackgroundHung, S., Chang, Y., Liu, J., Kuo, K., Chen, Y., Hsu, C.-C., & Tarng, D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00123-0 · Cited by 153
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Abdul-Ghani, M., DeFronzo, R. A., Del Prato, S., Chilton, R., Singh, R., & Ryder, R. E. J. (2017) · Diabetes Care · doi:10.2337/dc16-2736 · Cited by 145
Saito, Y., Okada, S., Ogawa, H., Soejima, H., Sakuma, M., Nakayama, M., Doi, N., Jinnouchi, H., Waki, M., Masuda, I., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025760 · Cited by 140
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145
“The benefits of glucose-lowering therapy should also be considered within a broader context of the patient’s life expectancy, because there is nearly a 10-year lag period to demonstrable benefit of more intensive glycemic control.(82,89) Moreover, treatment decisions need to consider potential benefits and harms of in…”
(2023) · doi:10.1002/14651858.cd013775.pub2 · Cited by 145
SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Saisho, Y. (2020) · Diseases · doi:10.3390/diseases8020014 · Cited by 185
“According to the results of UKPDS (UK Prospective Diabetes Study) [32], it has been assumed that the effect of glucose-lowering therapy to improve CV outcome appears after 5 to 10 years of treatment.”
ResultOral insulin – a review of current status
Iyer, H. V., Khedkar, A., & Verma, M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01150.x · Cited by 154
Neumiller, J. J. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09078 · Cited by 161
Wu, Z., Liu, L., Wang, W., Cui, H., Zhang, Y., Xu, J., Zhang, W., Zheng, T., & Yang, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01576-8 · Cited by 155
Thiazolidinedione Drugs and Cardiovascular Risks
Kaul, S., Bolger, A. F., Herrington, D. M., Giugliano, R. P., & Eckel, R. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.014 · Cited by 148
Wu, Y. H., Tang, L., & Chen, B. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/752387 · Cited by 152
“The phenomenon was termed “legacy effect” in the said publication [37].”
BackgroundGlucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M., Karagiannis, A., & Mikhailidis, D. P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 141
Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy—Friend or foe?
Yamagishi, S., & Matsui, T. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.05.009 · Cited by 164
The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence
Nordin, C. (2010) · Diabetologia · doi:10.1007/s00125-010-1752-6 · Cited by 157
“Indeed, follow-up studies from long-term cohorts with type 1 [95] and type 2 [96] diabetes have demonstrated that early aggressive lowering of HbA1c levels leads to a reduction of myocardial infarction and other measures of macrovascular disease 10 or more years later.”
Rosenstock, J., Marx, N., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Bluhmki, E., Patel, S., Johansen, O.-E., & Woerle, H.-J. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112475102 · Cited by 144
Gallo, L. A., Ward, M. S., Fotheringham, A. K., Zhuang, A., Borg, D. J., Flemming, N. B., Harvie, B. M., Kinneally, T. L., Yeh, S.-M., McCarthy, D. A., et al. (2016) · Scientific Reports · doi:10.1038/srep26428 · Cited by 143
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
“On the other hand, the 10-year follow-up data of the UKPDS (United Kingdom Prospective Diabetes Study) show that an early and effective diabetes treatment not only lowers microvascular complications, but also macrovascular endpoints significantly.([5]) In view of these findings, patients with newly diagnosed type 2 di…”
Addressing barriers to initiation of insulin in patients with type 2 diabetes
Peyrot, M. F., Rubin, R. R., & Khunti, K. (2010) · Primary care diabetes · doi:10.1016/s1751-9918(10)60004-6 · Cited by 149
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 175
“56,116 Other prospective randomized trials have confirmed reductions in a composite of CV events (CV death, all-cause deaths, non-fatal MI or stroke or arterial revascularization) by 46% after 5 years in metformin-treated compared with sulphonylurea-treated T2D.”
Herrington, W. G., Smith, M., Bankhead, C., Matsushita, K., Stevens, S., Holt, T., Hobbs, F. D. R., Coresh, J., & Woodward, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173515 · Cited by 141
Sönnichsen, A. C., Winkler, H., Flamm, M., Panisch, S., Kowatsch, P., Klima, G., Fürthauer, B., & Weitgasser, R. (2010) · BMC Family Practice · doi:10.1186/1471-2296-11-86 · Cited by 141
“However, the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that even small differences in HbA1c may translate into benefits regarding acute and chronic diabetic complications as well as hospital admissions in the long run [30].”
Dhatariya, K., Bain, S. C., Buse, J. B., Simpson, R., Tarnow, L., Kaltoft, M. S., Stellfeld, M., Tornøe, K., Pratley, R. E., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc18-1094 · Cited by 141
“Diamicron MR Controlled Evaluation (ADVANCE) studies, but DFU was not a specified end point in these trials (11,20,21).”
BackgroundEffects of Bilio-Pancreatic Diversion on Diabetic Complications
Iaconelli, A., Panunzi, S., De Gaetano, A., Manco, M., Guidone, C., Leccesi, L., Gniuli, D., Nanni, G., Castagneto, M., Ghirlanda, G., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1761 · Cited by 141
Strategies and Challenges in Clinical Trials Targeting Human Aging
Newman, J. C., Milman, S., Hashmi, S. K., Austad, S. N., Kirkland, J. L., Halter, J. B., & Barzilai, N. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw149 · Cited by 138
“It has been extensively studied and was shown to delay T2DM, reduce CVD, and improve overall survival (44,89,90).”
BackgroundBergenstal, R. M. (2015) · Diabetes Care · doi:10.2337/dc15-0099 · Cited by 140
“the long-term development of CVD and mortality (5).”
BackgroundOn behalf of the EUROASPIRE Investigators, Gyberg, V., De Bacquer, D., De Backer, G., Jennings, C., Kotseva, K., Mellbin, L., Schnell, O., Tuomilehto, J., Wood, D., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0296-y · Cited by 140
“It has become apparent from randomised trials that the reduction of macrovascular events by glucose-lowering strategies has yet to be proven and may only be seen after many years of follow-up [21, 28].”
BackgroundPathak, R. D., Schroeder, E. B., Seaquist, E. R., Zeng, C., Lafata, J. E., Thomas, A., Desai, J., Waitzfelder, B., Nichols, G. A., Lawrence, J. M., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0858 · Cited by 140
“In 2008, results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) (10), Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) (11), and Veterans Affairs Diabetes Trial (VADT) (12) trials, followup from the Steno-2 (13) and UKPDS (14) trials, a…”
BackgroundOxidative stress: A cause and therapeutic target of diabetic complications
Araki, E., & Nishikawa, T. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00013.x · Cited by 138
Ho, J. Y. S., So, K., & Chang, R. C. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.10.001 · Cited by 156
“Tight blood glucose control can reduce disease complications (Holman et al., 2008), and may also result in cognitive improvement in diabetes patients (Beeri et al.”
Mitochondria as a therapeutic target for cardiac ischemia‑reperfusion injury (Review)
Marin, W., Marin, D., Ao, X., & Liu, Y. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4823 · Cited by 149
“and clinical studies (such as the dIGAMI 2 trial) have suggested the cardioprotective effects of metformin against IR injury (118-121), 4 months of metformin treatment in the GIPS-III trial did not result in improved left ventricular function in patients without diabetes presenting with STEMI.”
BackgroundBouchi, R., Sugiyama, T., Goto, A., Imai, K., Ihana‐Sugiyama, N., Ohsugi, M., Yamauchi, T., Kadowaki, T., & Ueki, K. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13636 · Cited by 154
Long-Term Weight Loss Strategies for Obesity
Kheniser, K., Saxon, D. R., & Kashyap, S. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab091 · Cited by 139
“Treating hyperglycemia with pharmacotherapy can reduce all-cause mortality and CVD risk (142).”
Epigenetic Changes in Diabetes and Cardiovascular Risk
Keating, S. T., Plutzky, J., & El-Osta, A. (2016) · Circulation Research · doi:10.1161/circresaha.116.306819 · Cited by 139
“Comparable findings were reported for type 2 diabetes in the United Kingdom Prospective Diabetes Study, where despite equalization of HbA1 c , 10-year follow-up demonstrated a persistent reduction in vascular complications in those initially assigned intensive glycemic control when compared with conventional therapy.(…”
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
Swinnen, S. G., Simon, A. C., Holleman, F., Hoekstra, J. B., & DeVries, J. H. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006383.pub2 · Cited by 137
Strain, W. D., Lukashevich, V., Kothny, W., Hoellinger, M.-J., & Paldánius, P. M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60995-2 · Cited by 140
Haak, T., Meinicke, T., Jones, R., Weber, S., Eynatten, M. V., & Woerle, H. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01590.x · Cited by 140
“In the 10-year follow-up of the United Kingdom Prospective Diabetes Study, early, intensive pharmacotherapy had long-term benefits, in terms of reducing the incidence of microvascular complications and cardiovascular events [35].”
BackgroundMarino, A., Hausenloy, D. J., Andreadou, I., Horman, S., Bertrand, L., & Beauloye, C. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.047 · Cited by 148
60 years of metformin use: a glance at the past and a look to the future
Marshall, S. M. (2017) · Diabetologia · doi:10.1007/s00125-017-4343-y · Cited by 150
Ye, X., Kong, W., Zafar, M. I., & Chen, L.-L. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0851-z · Cited by 138
Pharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
Kearney, K., Tomlinson, D., Smith, K., & Ajjan, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0515-9 · Cited by 130
Death during intensive glycemic therapy of diabetes: mechanisms and implications
Cryer, P. E. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.008 · Cited by 137
Insulin use and increased risk of mortality in type 2 diabetes: a cohort study
Gamble, J. ‐., Simpson, S. H., Eurich, D. T., Majumdar, S. R., & Johnson, J. A. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01125.x · Cited by 136
“The long-term follow-up results from the UKPDS [21] reported a 13% reduction for all-cause mortality in patients receiving ‘intensive’ therapy with sulfonylureas (+/− insulin), consistent with observational data suggesting a 14% decrease in all-cause mortality for every 1% reduction in A1C [22].”
BackgroundResultFeng, S., Yu, H., Yu, Y., Geng, Y., Li, D., Yang, C., Lv, Q., Li, L., Liu, T., Li, G., et al. (2018) · Journal of Diabetes Research · doi:10.1155/2018/8546423 · Cited by 150
Zinman, B., Inzucchi, S. E., Lachin, J. M., Wanner, C., Fitchett, D., Kohler, S., Mattheus, M., Woerle, H. J., Broedl, U. C., Johansen, O. E., et al. (2017) · Stroke · doi:10.1161/strokeaha.116.015756 · Cited by 136
Green, J. B., Bethel, M. A., Paul, S. K., Ring, A., Kaufman, K. D., Shapiro, D. R., Califf, R. M., & Holman, R. R. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.09.003 · Cited by 141
Self-citationOlsen, A. S., Sarras, M. P., Leontovich, A. A., & Intine, R. V. A. (2012) · Diabetes · doi:10.2337/db11-0588 · Cited by 139
From Hong Kong Diabetes Register to JADE Program to RAMP-DM for Data-Driven Actions
Chan, J. C. N., Lim, L.-L., Luk, A. O. Y., Ozaki, R., Kong, A. P. S., Ma, R. C. W., So, W.-Y., & Lo, S.-V. (2019) · Diabetes Care · doi:10.2337/dci19-0003 · Cited by 133
Andreadi, A., Bellia, A., Daniele, N. D., Meloni, M., Lauro, R., Della‐Morte, D., & Lauro, D. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.010 · Cited by 144
The FLAT-SUGAR Trial Investigators (2016) · Diabetes Care · doi:10.2337/dc15-2782 · Cited by 135
“26 weeks 45 3,967 (4,197) 1,625 (5,642) 43 2,583 (3,011) 1,113 (3,129) 0.”
Tarāsova, L., Kalniņa, I., Geldnere, K., Bumbure, A., Ritenberga, R., Ņikitina-Zaķe, L., Frīdmanis, D., Vaivade, I., Pīrāgs, V., & Kloviņš, J. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283561666 · Cited by 149
Partnering with diabetes educators to improve patient outcomes
Burke, S., Sherr, D., & Lipman, R. D. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s40036 · Cited by 154
“It has been said that the expected benefits from diabetes treatment, such as the reductions in risk of diabetic eye disease, kidney disease, or heart disease, may take many years to become apparent.(7) However, results from the ongoing Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions an…”
ResultThe Treatment of Type 2 Diabetes
Pfeiffer, A. F. H., & Klein, H. H. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0069 · Cited by 209
Durante, W., Behnammanesh, G., & Peyton, K. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168786 · Cited by 139
“Intriguingly, the reduction of adverse cardiovascular events occurs rapidly following the start of therapy, suggesting that mechanisms other than improvements in hyperglycemia are responsible for this effect as glycemic control requires years to have a measureable impact [41,42].”
BackgroundInfluentialKamuhabwa, A., & Charles, E. (2014) · Drug, Healthcare and Patient Safety · doi:10.2147/dhps.s68786 · Cited by 132
Effects of intermittent fasting on health markers in those with type 2 diabetes: A pilot study
Arnason, T. G., Bowen, M. W., & Mansell, K. D. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i4.154 · Cited by 126
Rossi, M. C., Nicolucci, A., Ozzello, A., Gentile, S., Aglialoro, A., Chiambretti, A., Baccetti, F., Gentile, F. M., Romeo, F., Lucisano, G., et al. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.04.009 · Cited by 132
RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
Bajaj, S. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0604-7 · Cited by 125
Carlsson, L. M. S., Sjöholm, K., Karlsson, C., Jacobson, P., Andersson-Assarsson, J. C., Svensson, P.-A., Larsson, I., Hjorth, S., Neovius, M., Taube, M., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30061-x · Cited by 126
Wan, E. Y. F., Fung, C. S. C., Jiao, F. F., Yu, E. Y. T., Chin, W. Y., Fong, D. Y. T., Wong, C. K. H., Chan, A. K. C., Chan, K. H. Y., Kwok, R. L. P., et al. (2018) · Diabetes Care · doi:10.2337/dc17-0426 · Cited by 126
Devasenathipathy, R., Mani, V., Chen, S., Huang, S., Huang, T., Lin, C., Hwa, K., Chen, T.-Y., & Chen, B.-J. (2015) · Enzyme and Microbial Technology · doi:10.1016/j.enzmictec.2015.06.006 · Cited by 132
Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial
Zhou, J. J., Schwenke, D. C., Bahn, G., & Reaven, P. (2018) · Diabetes Care · doi:10.2337/dc18-0548 · Cited by 131
Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?
Mannucci, E., Dicembrini, I., Lauria, A., & Pozzilli, P. (2013) · Diabetes Care · doi:10.2337/dcs13-2018 · Cited by 127
“On the other hand, despite some encouraging results (2,3), the results of trials assessing the long-term cardiovascular effects of improving metabolic control in type 2 diabetes are controversial.”
BackgroundIntensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial
Schwartz, A. V., Margolis, K. L., Sellmeyer, D. E., Vittinghoff, E., Ambrosius, W. T., Bonds, D. E., Josse, R. G., Schnall, A. M., Simmons, D. L., Hue, T. F., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2184 · Cited by 132
Ross, S., Gerstein, H. C., Eikelboom, J., Anand, S. S., Yusuf, S., & Paré, G. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv083 · Cited by 129
Screening for Diabetes and Prediabetes
Duan, D., Kengne, A. P., & Echouffo-Tcheugui, J. B. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.002 · Cited by 145
Epigenetic programming, early life nutrition and the risk of metabolic disease
Block, T., & El-Osta, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.003 · Cited by 130
Epigenetics: deciphering its role in diabetes and its chronic complications
Villeneuve, L. M., Reddy, M. A., & Natarajan, R. D. (2011) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05497.x · Cited by 137
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.016 · Cited by 149
Akhtar, S., Mohan, V., Shah, S., Joshi, S., Seshiah, V., Bk, S., Banerjee, S., Wangnoo, S., Kumar, A. M. V., Kalra, S., et al. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.129715 · Cited by 130
“[13] Additionally, good glycaemic control is an important component of cardiovascular disease prevention and treatment.[14] An early intensive glycaemic control reduces the risk of diabetic complications and has long-term infl uence of early metabolic control on clinical outcomes.”
Sacks, D. B. (2012) · Diabetes Care · doi:10.2337/dc12-1348 · Cited by 124
“The goal of theNGSP is to standardize glycated hemoglobin test results to those of the DCCT and UKPDS, which established direct relationships between HbA1c concentrations and outcome risks Table 2dSpecies of modified HbA Name Site Modification A1a1 NH2 terminus of the b-chain Fructose 1,6-diphosphate A1a2 NH2 terminus…”
BackgroundInfluentialDiabetic Kidney Disease: Past and Present
Akhtar, M., Taha, N. M., Nauman, A., Mujeeb, I., & Al-Nabet, A. D. M. H. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000257 · Cited by 143
Sasso, F. C., Pafundi, P. C., Simeon, V., De Nicola, L., Chiodini, P., Galiero, R., Rinaldi, L., Nevola, R., Salvatore, T., Sardu, C., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01343-1 · Cited by 129
“Besides the well-known effects of BP lowering treatment with RAS inhibition, the intensive glycaemic control with the consequent “legacy effect” on AGEs [33], the effect of statin on LDL and inflammatory cytokines [34, 35], and the inhibition of platelet adhesion, which reduces leukocyte infiltration and atheroscleros…”
BackgroundPanretinal Photocoagulation for Proliferative Diabetic Retinopathy
Bressler, N. M., Beck, R. W., & Ferris, F. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmct0908432 · Cited by 124
Prattichizzo, F., De Nigris, V., La Sala, L., Procopio, A. D., Olivieri, F., & Ceriello, A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1810327 · Cited by 129
Metformin Beyond Diabetes: Pleiotropic Benefits of Metformin in Attenuation of Atherosclerosis
Forouzandeh, F., Salazar, G., Patrushev, N., Xiong, S., Hilenski, L., Fei, B., & Alexander, R. W. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001202 · Cited by 126
“are several clinical studies that strongly suggest its superiority in improving survival compared with other standard medications in patients with DM2 even at similar glycemic levels.(14,18,53) Also, data from clinical studies confirm a modest effect of metformin on attenuation of blood pressure.”
ResultMcIntosh, B., Cameron, C. G., Singh, S. R., Yu, C., Ahuja, T. K., Welton, N. J., & Dahl, M. (2011) · PubMed Central · Cited by 157
The Role of MicroRNAs in Diabetic Complications—Special Emphasis on Wound Healing
Moura, J., Børsheim, E., & Carvalho, E. (2014) · Genes · doi:10.3390/genes5040926 · Cited by 134
“This is supported by the UKPDS and STENO-2 studies, where treatment of chronic hyperglycemia was undertaken at the early stages of the disease [17,18].”
ResultChamberlain, J. J., Herman, W. H., Leal, S., Rhinehart, A. S., Shubrook, J. H., Skolnik, N., & Kalyani, R. R. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2937 · Cited by 127
“It is effective, safe, and inexpensive and may reduce the risk for cardiovascular events and death (2).”
BackgroundWang, X., Feng, B., Huang, Z., Cai, Z., Yu, X., Chen, Z., Cai, Z., Chen, G., Wu, S., & Chen, Y. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01510-y · Cited by 136
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 150
“Therefore, the long-term maintenance of glycemic control within the near-normal range is critical for patients with diabetes [11].”
Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88
Lind, M., Imberg, H., Coleman, R. L., Nerman, O., & Holman, R. R. (2021) · Diabetes Care · doi:10.2337/dc20-2439 · Cited by 128
“Population The UKPDS design and results have been described previously (1,3,7,8).”
BackgroundMethodResultInfluentialSelf-citationAndreozzi, F., Candido, R., Corrao, S., Fornengo, R., Giancaterini, A., Ponzani, P., Ponziani, M. C., Tuccinardi, F., & Mannino, D. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00559-7 · Cited by 128
Babij, K., Anna, D., Szołtysik, M., Pokora, M., Zambrowicz, A., & Chrzanowska, J. (2014) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-014-9413-0 · Cited by 135
“The contemporary therapeutic approach to diabetes is to decrease postprandial hyperglycemia, as strict glycemic control reduces the microvascular complications (Holman et al. 2008).”
BackgroundSitagliptin: A Review of its Use in the Management of Type 2 Diabetes Mellitus
Dhillon, S. (2010) · Drugs · doi:10.2165/11203790-000000000-00000 · Cited by 140
Megatrials in type 2 diabetes. From excitement to frustration?
Prato, S. D. (2009) · Diabetologia · doi:10.1007/s00125-009-1352-5 · Cited by 135
“Conversely, in both type 1 [28, 29] and type 2 [30] diabetic patients, early strict glycaemic control generates a legacy that may confer protection against, or delay, long-term diabetic complications.”
BackgroundRAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy
Matsui, T., Higashimoto, Y., Nishino, Y., Nakamura, N., Fukami, K., & Yamagishi, S. (2017) · Diabetes · doi:10.2337/db16-1281 · Cited by 133
“Epidemiological studies have supported the concept of metabolic memory in the development and progression of vascular complications in diabetes (40-43).”
BackgroundImaging and Biomarkers in Diabetic Macular Edema and Diabetic Retinopathy
Kwan, C. C., & Fawzi, A. A. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1226-2 · Cited by 141
Honigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127
The benefits of GLP1 receptors in cardiovascular diseases
Ferhatbegović, L., Mršić, D., & Macić-Džanković, A. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1293926 · Cited by 127
“Maintaining stable blood glucose levels through lifestyle modi fi cations and medications can mitigate the adverse effects of hyperglycemia on blood vessels, thereby contributing to CVD risk reduction in diabetic patients (48, 49).”
Background
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.